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Abstract: There has been a remarkable transformation in the treatment of chronic hepatitis C in
recent years with the development of direct acting antiviral agents targeting virus encoded proteins
important for viral replication including NS3/4A, NS5A and NS5B. These agents have shown high
sustained viral response (SVR) rates of more than 90% in phase 2 and phase 3 clinical trials; however,
this is slightly lower in real-life cohorts. Hepatitis C virus resistant variants are seen in most patients
who do not achieve SVR due to selection and outgrowth of resistant hepatitis C virus variants within
a given host. These resistance associated mutations depend on the class of direct-acting antiviral
drugs used and also vary between hepatitis C virus genotypes and subtypes. The understanding of
these mutations has a clear clinical implication in terms of choice and combination of drugs used. In
this review, we describe mechanism of action of currently available drugs and summarize clinically
relevant resistance data.
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1. Introduction
Hepatitis C virus (HCV) infection is a major global health problem and a leading cause of
morbidity and mortality. The most recent estimate showed an increase in the prevalence of HCV
infection over last 15 years from 2.3% to 2.8%. This equates to 170 million people who are chronically
infected worldwide and 3–4 million developing new infection with HCV each year [1,2] while
350,000 people die every year due to HCV related complications [3].
Following exposure to HCV, only a minority of cases are able to clear the virus spontaneously.
The majority of individuals (approximately 80%) develop chronic infection with persistent viremia
and chronic hepatitis. This frequently results in the development of progressive liver fibrosis and
ultimately cirrhosis, with its attendant risks of developing liver failure and hepatocellular cancer [2,4].
Until 2011, HCV standard-of-care treatment consisted of interferon alpha and ribavirin for
several months, which is associated with detrimental side effects affecting compliance and poor
outcomes. However, new and promising direct-acting antiviral agents (DAAs) have recently
become available with more in the development pipeline resulting in a remarkable transformation
in treatment of HCV. DAAs are drugs targeting specific HCV encoded proteins resulting in
disruption of the viral life cycle. A number of DAAs are either approved or in phases of advanced
development and clinical trials. The first generation of DAAs was administered in conjunction
with pegylated interferon, so while the efficacy of treatment increased, the issues with side-effects
remained. However, the incorporation of next-generation DAAs into the antiviral cocktail is leading
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to interferon-free regimens in clinical practice. Although the first generation of DAAs (NS3/4A
inhibitors Telaprevir and Boceprevir) were co-administered with pegylated interferon and ribavirin,
thereby adding to the side effect burden [5,6], the second generation of DAAs have minimal side
effects, are efficacious with shortened courses of treatment, and are associated with cure rates of more
than 90% in phase II and III studies.
The initial observations with these DAA regimens in various real-world cohorts also show
high SVR rates of 80%–90% but they are slightly lower than those seen in registration studies.
For example, the first approved interferon-free regimens for treating genotype 2 and 3 infection
included a combination of sofosbuvir (an NS5B inhibitor) and ribavirin for 12 to 24 weeks. This
resulted in an SVR of 68%–90% [7–10]. DAA combinations currently recommended to treat genotype
3 infection include NS5B polymerase inhibitor sofosbuvir and NS5A inhibitor daclatasvir with or
without ribavirin while a combination of sofosbuvir and ribavirin is recommended for treatment
of HCV genotype 2 infection, with possible addition of pegylated interferon alpha in patients with
previous treatment failure. Other DAA combinations available to treat genotype 1 infection include
sofosbuvir with either of the two NS5A inhibitors daclatasvir or ledispavir, a regimen consisting
of ombitasvir-paritaprevir-ritonavir, and either dasbuvir or simeprevir with sofosbuvir. Treatment
choice depends on HCV genotype, presence of cirrhosis, Child Pugh Class and previous HCV
treatment experience. The above findings and extensive use of these drugs in the near future predicts
that a proportion of patients will fail to achieve SVR and develop resistance.
HCV exists as a heterogeneous pool of genetic variants within an infected individual prior to
treatment. This is due to the high error rate of HCV polymerase introducing on average one mutation
per replicant and high rate of virion production [11,12]. Certain polymorphisms, which are resistant
to direct acting antivirals, can exist at low levels prior to treatment and may get selected upon
exposure to these drugs. In this review, we discuss DAAs according to their mechanism of action,
drug resistance profiles, and discuss clinical applications where relevant.
2. Emergence of DAA Resistance
HCV has higher sequence diversity even within an individual genotype in comparison to other
chronic viral infections such as hepatitis B virus or HIV [13]. HCV has a high turnover rate with
an estimated half-life of only 2–5 h with 1010 to 1012 virions produced and cleared per day in an
infected patient [11,14–16]. Because of lack of proof reading activity of HCV RNA dependent RNA
polymerase (NS5B) [12,17] and high replication activity of HCV, a large number of viral variants are
produced continuously during infection with an error rate of 10´3 to 10´4 mutations per nucleotide
per genomic replication [17]. Most of these variants are cleared by the host immune system or are
unable to replicate because of a functional loss in encoded proteins [18,19]. Thus a heterogeneous
mixture of closely related genomes comprising a dominant strain (wild type strain) along with other
strains present at lower frequencies makes up the HCV population in a given host. This pool of
variants is termed the quasispecies in the host. This quasispecies existence of HCV in a given host
results in a significant adaptation advantage because the simultaneous presence of multiple variant
genomes allows for on-going evolutionary selection of mutations with better fitness to any given
condition. A classic example of this is the adaptation of the quasispecies that occurs post-liver
transplantation [20]. Hence, HCV variants with a different level of susceptibility may exist naturally
at low levels in the absence of drug pressure and can be selected in patients with suboptimal response
to treatment [21]. The biological and clinical implication of this selection is resistance to direct acting
antiviral agents and treatment failure.
Relapse of HCV in patients who initially respond to DAA may be due to the replication of a
residual variant that remained below the limit of detection at the end of treatment. Viral sequencing
at the time of relapse may identify the virus sequence present at the end of treatment but it is also
possible for viral population to evolve to wild type prior to sequencing after relapse, as it is not under
selective pressure at the time.
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3. Direct Acting Antiviral Drugs
The HCV genome is composed of a 9kb open reading frame flanked by a 5’ and 3’ untranslated
region. The genome is translated into a polyprotein that is cleaved to form structural (Core, E1, E2)
and non-structural proteins (p7, NS2, NS3, NS4a, NS4b, NS5A and NS5). DAAs have been developed
to target non-structural viral proteins involved in viral replication. These include NS3-4A inhibitors,
NS5A inhibitors and nucleoside and non-nucleoside inhibitors of NS5B (Figure 1). However, studies
have shown that various breakthrough viral mutations in viral proteins can confer resistance to the
respective DAAs (Figure 1).
The mechanism of action of these DAAs and evidence for breakthrough resistance mutations in
the light of current evidence is discussed below.
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Figure 1. The HCV genome encodes a single open reading frame flanked by 5’ and 3’ untranslated
regions (UTR). Cleavage of this polyprotein by host endopeptidases (for structural proteins) and viral
non-structural protein NS3/4A results in producing structural proteins core (C), Envelope proteins 1
and 2 (E1, E2), and n -structural proteins p7, NS2, NS3, NS4A, NS4B, NS4A, an NS5B. Enzymatic
functio of non-structural proteins has been the basis of DAAs (outlin in red). These can be
overcome by common breakthrough mutations (circled and highlighted).
3.1. NS3-4A Protease Inhibitors
The target for these agents is the viral protease NS3/4A essential for cleaving the HCV encoded
polyprotein into individual viral proteins facilitating replication. It is a heterodimer complex of NS3
and NS4A proteins. NS3 possesses the proteolytic site while NS4 is a cofactor. The NS3/4A protease
cleaves the HCV polyprotein generating non-structural viral proteins NS3, NS4A, NS4B, NS5A and
NS5A. NS3/4A inhibitor block the NS3 catalytic ite or inhibit NS3/4A interacti n th reby blocking
HCV p lyprotein cleavage [22].
In addition to this direct action, they may also help recover innate immune processes.
NS3/4A protease blocks Toll/interleukin-1 receptor domain-containing adaptor inducing IFN-β
(TRIF) mediated Toll-like receptor signalling, as well as mitochondrial antiviral signalling protein
6718
Viruses 2015, 7, 6716–6729
(MAVS, also termed IPS-1, VISA, and CARDIF) mediated RIG-I signalling [23,24] which then results
in impaired interferon induction [25]. Therefore, it is possible that inhibition of this protease also
helps recover interferon production.
The catalytic site on NS3 protease consists of the amino acid triad serine-histidine-aspartate and
is located in a shallow substrate binding groove with solvent features which does not facilitate tight
binding to the inhibitors [26]. Therefore, inhibitors depend on few interactions with the enzyme and
only a few critical mutations in the enzyme may be enough to confer significant resistance to these
drugs [27–29].
First generation NS3/4A protease inhibitors include boceprevir and telaprevir which were the
first DAA approved for treating chronic HCV genotype 1 and achieved significantly higher SVR rates
when given in combination with pegylated interferon and ribavirin compared to previous standard
treatment consisting of pegylated interferon and ribavirin alone. They are given in combination
with pegylated interferon and ribavirin as the efficacy of these combination regimens still largely
relies on the viral sensitivity to interferon. This combination has shown a higher SVR in previous
partial responders or relapsers to combination of pegylated interferon and ribavirin than with null
responders. The virus has a low genetic barrier to development of resistance to both boceprevir
and telaprevir. Baseline sequencing analysis for the presence of amino acid substitutions in the
NS3/4A region has shown detectable resistance associated variants (RAVs) in patients with HCV
genotype 1 pre-treatment [27,28,30]. These are present in 8.6% of treatment naïve GT1a and 1.4% of
treatment naïve GT1b population [30]. However, their presence did not always preclude treatment
success [27,28]. On the other hand, the majority of patients who did not achieve SVR had detectable
resistant variants at the time of treatment failure [27]. Baseline testing for these variants regarding
clinical outcome is therefore not recommended [31,32].
Analysis of HCV sequences in patients who did not achieve SVR with telaprevir based regimen
in phase 2 and 3 studies identified following variants as being significantly enriched: V36A/M,
T54A/S, R155K/T, A156S/T and D168N [27]. These amino acid positions associated with resistance
are located near the protease catalytic site in the NS3 protease domain, consistent with the mechanism
of action of a protease inhibitor. Kieffer et al. [27] in the same study also performed enzymatic and
replicon based phenotypic studies to show that these mutations confer different levels of resistance to
telaprevir in vitro. Variants conferring low level resistance were defined as a 3–25 fold increase in IC50
from wild-type whilst those conferring high level had >25 fold increase in IC50. Interestingly, almost
all the viral breakthroughs during telaprevir treatment were associated with high-level resistant
variants [27].
Breakthrough variants tend to be less efficient at replication, therefore they are replaced by
primary variants once selection pressure from treatment ceases. Sequence analysis of HCV during
follow up from patients who did not achieve SVR in phase 3 studies of telaprevir based therapy
suggests replacement of resistant variants with wild type virus over a median time period of
10 months for genotype 1a and three weeks for genotype 1b infection [27,33,34]. It may therefore
be possible to treat these individuals with alternative treatment options.
Second-generation NS3/4A protease inhibitors have improved potency but the problem of
low genetic barrier to developing resistance remains with these agents. These second generation
inhibitors include simeprevir, paritaprevir and asunaprevir. Asunaprevir is available in Japan, whilst
grazoprevir is in phase 3 clinical trials. Population based sequencing identified a key clinically
relevant polymorphism Q80K which was found in 19%–48% of NS3 protease sequences from
genotype 1a [35]. In vitro studies have shown that Q80K decreases viral susceptibility to simeprevir
by 10-fold [36]. Less profound decreases in viral susceptibility were seen to other second line NS3
inhibitors including sovaprevir and asunaprevir [37]. These findings were supported in vivo in
phase 2 and phase 3 clinical trials assessing simeprevir with pegylated IFN and ribavirin in genotype
1 patients [35,38]. Patients infected with HCV genotype 1 with baseline Q80K polymorphism have
a significantly lower rate of achieving SVR relative to those without this polymorphism (58% vs.
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84%). It is therefore clinically recommended to perform baseline resistance testing for this mutation
in genotype 1a patients and to avoid simeprevir treatment when this polymorphism is present. A
recent interim analysis from an open label study which assessed simeprevir in combination with
daclatasvir and sofosbuvir in a small number of patients with advanced liver disease showed that
all patients achieved SVR12 (sustained viral response at 12 weeks post treatment) including patients
with baseline Q80K or NS5A polymorphism showing the strength of combinatorial treatment [39].
Resistance mutations emerging during unsuccessful treatment with first-generation protease
inhibitors have been associated with decreased in vitro susceptibility to simeprevir and are therefore
also expected to have an impact on clinical outcome.
3.2. NS5A Inhibitors
NS5A protein is involved in viral replication, assembly, and release of HCV particles [40–42].
NS5A protein has three domains. These are N terminus domain I (amino acids 1–213), domain II
(amino acids 250–342) and C–terminus domain III (amino acids 356–447) [43]. Domains I and II are
involved in RNA replication while domain III is essential for virion assembly. NS5A inhibitors such as
daclatasvir block replication of HCV RNA as well as virus assembly. In particular, inhibitor binding
to NS5A results in conformational changes thereby preventing NS5A interaction with membranous
and cellular proteins. This, in turn, abrogates the formation of membranous web, which is the virus
induced membrane compartment where RNA replication occurs. [41,42,44,45]
Currently, available NS5A inhibitors are daclatasvir, ledipasvir and ombitasvir. The latter two
are available in fixed dose combinations with other direct acting antiviral agents. Elbasvir and
Veltapasvir are being studiedin phase 3 clinical trials in combination with NS3 inhibitor grazoprevir
and the NS5B inhibitor sofosbuvir, respectively. Amongst these, daclatasvir targets NS5A domain
I. Although NS5A inhibitors are quite potent and have a broad genotypic coverage, they are also
associated with a relatively low viral barrier to resistance and long-time persistence of RAVs.
Daclatasvir is associated with a higher response in genotype 1b compared to 1a, which is
also explained by the higher barrier to resistance by genotype 1b. In genotype 1a, selection of
a single mutation is enough to lose susceptibility to daclatasvir [46,47]. In genotype 1b, single
amino acid substitution and some double amino acid substitutions (Q54H-Y93H) conferred minimal
resistance. However, some double substitutions (L31V-Y93H) in G1b are associated with a high level
of resistance [47]. Polymorphisms of NS5A protein that have been associated with resistance both
in vitro and in vivo include variants at amino acids M28, A30, L31 and Y93 for genotype 1a and L31
and Y93 for genotype 1b [47].
Naturally occurring polymorphisms in NS5A may also influence susceptibility to daclatasvir.
Such polymorphisms are less common in genotype 1a and 3 but much more common in genotype 1b
and 4. In genotype 2, mutation L31M is seen in 50%–85% but clinical trials have shown that it does
not predict treatment failure in a study where it was given in combination with pegylated interferon
alpha and ribavirin [48]. Subsequent Phase III clinical trials of daclatasvir with asunaprevir (NS3/4A
inhibitor) have shown that the presence of baseline polymorphisms at amino acids L31 and Y93 is
associated with loss of susceptibility to NS5A inhibitors [49].
A recent large study evaluating NS5A RAVs in samples from genotype 1a infected patients
from 22 different countries treated with a combination of sofosbuvir and NS5A inhibitor ledipasvir
did not show any difference in baseline prevalence of these variations between different regions
and ethnicities. However, in genotype 1a patients, lower SVR 12 rate was observed in patients
with pretreatment NS5A resistant associated variants conferring high level (>1000 fold) resistance
to NS5A inhibitors when treated for 24 weeks. These included H58D, Y93H/N/F or multiple RAV
combinations. The largest impact of RAVs on treatment outcome was observed in patients with
cirrhosis treated for 24 weeks with sofosbuvir and ledipasvir. However, SVR rates were similar in
genotype 1b patients with and without pretreatment NS5A RAVs. The same study also reported that
IL28B-CC genotype is significantly associated with a higher prevalence of Y93H [50]. This association
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has been reported previously but currently not functionally understood and clinical relevance needs
to be defined further. This may, however, explain a lack of or even inverse correlation of treatment
response with IL28B genotype in some NS5A inhibitor containing IFN-free regimens [51].
One of the key resistance determinants associated with amino acid substitution, Y93H was
also detected as a natural baseline polymorphism in 13 out of 148 genotype 3 patients in a clinical
trial of daclatasvir and sofosbuvir. This was also associated with lower SVR rates [52]. The
relevance of breakthrough mutations in the context of NS5A inhibitors is reflected in that common
mutational analysis is commercially available in the USA, although baseline testing is not currently
recommended by guidelines. DAA combinations that target multiple targets and include sofosbuvir
may be a strategy to treat patients with NS5A resistant associated variants.
An emerging problem that has been revealed with NS5A inhibitors is the extensive persistence
of NS5A RAVs post-treatment, possibly even indefinitely [53]. However, renewed hope in NS5A
inhibitors is restored with a recent report that daclatasvir when used with an analogue molecule
restores its potency >1000 fold presumably through NS5A-NS5A interactions [54].
It is probable that due to protein-protein interactions during HCV replication, mutational
changes in other proteins including NS3, NS4B and NS5B can also influence susceptibility to NS5A
inhibitors. The analysis of single breakthrough mutations may be simplistic given that these
non-structural proteins work harmoniously for efficient HCV replication. Likewise, the role of
secondary structure within the RNA genome is also a consideration in replication efficiency.
3.3. NS5B Inihibitors
NS5B is an RNA dependent RNA polymerase which is involved in the processing of the
viral RNA genome to make a negative strand template and subsequently transcription of daughter
copies of the genome [55]. The enzyme is structurally organised in a characteristic “right hand
motif” which contains palm and thumb domains. It has two sites: a catalytic site for nucleoside
binding and four other sites responsible for allosteric alteration where non-nucleoside compounds
can bind. Therefore, there are two classes of polymerase inhibitors: nucleoside analogues also
called nucleoside polymerase inhibitors (NPI) and also non-nucleoside analogues also called
non-nucleoside polymerase inhibitors (NNPI).
The structure of RNA dependent RNA polymerase is highly conserved across all HCV
genotypes, thereby making these agents efficacious against all six HCV genotypes [22].
3.3.1. Nucleoside Polymerase Inhibitors (NPI)
NPIs are activated within hepatocytes through phosphorylation to nucleoside triphosphate,
which competes with nucleotide substrates that are incorporated into the nascent RNA chain
resulting in chain termination during RNA replication of viral genome [56].
The advantage of these agents is a very high barrier of viral genetic resistance. The active
(catalytic) site of NS5B is relatively intolerant to amino acid substitutions. Hence, active site mutations
that confer resistance to NPI are also likely to impair RNA polymerase activity compared with the
mutations in NNPI allosteric binding sites thereby making the mutant virus less fit compared with
the wild type virus by seriously impairing viral replication. S282T is one such mutation that was
idenfitied in vitro, however it has rarely been detected in patients with treatment failure in clinical
trials as mentioned later in this article.
Sofosbuvir is the first NS5B NPI to become available. Resistance variants within NS5B
polymerase have been reported with in vitro exposure to sofosbuvir although their clinical
significance is not entirely clear. These variants include S282T, L159F and E341D. In vitro studies
using HCV replicon systems, S282T was most commonly selected in all genotypes but mainly
conferred resistance to G1a and G1b with only a modest resistance in G2a replicon harbouring this
mutation [57]. These studies also showed that although S282T mutation was selected alone in G1b,
in G1a an additional mutation I434M was selected along with S282T on exposure to sofosbuvir. In
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the case of G2a, S282T together with other mutations T179A (finger domain), M289L and I293L (palm
domain) were essential for conferring resistance to sofosbuvir.
Amongst these, S282T mutation has infrequently been associated with reduced susceptibility
to sofosbuvir in vivo [58]. In the ELECTRON sofosbuvir monotherapy study, the S282T substitution
was detected in a patient infected with HCV genotype 2 who had a virological relapse Week 4 post
treatment [59]. It was also detected in a single patient who relapsed after 24 weeks treatment with
sofosbuvir and ribavirin who had virological relapse in the National Institutes of Health (NIH) SPARE
trial [60]. In a pooled analysis of sofosbuvir phase 3 trials involving patients infected with HCV
genotype 3 who did not achieve SVR, the substitutions L159F and V321A were selected post baseline
in several cases. In addition, substitutions C316N/H/F were present at baseline in in six patients
with HCV genotype 1b who failed treatment and one patient with genotype 1a who experienced
relapse [56]. In another recent pooled analysis of phase 2 and 3 studies where sofosbuvir based
regimen was administered, no S282T variant was detected at baseline. Emergence of this variant was
infrequent (1%) in subjects who had virlogical failure. S282T levels declined on average by four fold
within two weeks of follow up period confirming low replication fitness of this variant [61].
3.3.2. Non-Nucleoside Polymerase Inhibitors (NNPI)
Non-nucleoside polymerase inhibitors interact with RNA-dependent RNA-polymerases at one
of the four non catalytic allosteric binding sites and prevent conformational changes in the enzyme
crucial for its function. They can be subclassified based on their allosteric binging site: Palm 1, Palm 2,
Thumb1 and Thumb2 [62].
These agents have lowest barrier to resistance amongst all DAA. Consequently, they have
been used and studied in combination with other DAA as a part of multitarget strategy involving
non-overlapping drug targets to overcome RAVs to individual drugs. They do not exhibit cross
resistance with NPI given their different site and mechanism of action. Examples of these agents are
dasabuvir, which acts at Palm 1 site of RNA polymerase, and Baclabuvir, which acts at Thumb 1 site.
In vitro studies of dasabuvir using genotype 1 replicons showed that C316Y variant in both
genotype 1a and 1b and Y448C/H in genotype 1b conferred >900 fold resistance to dasabuvir. Other
amino acid substitutions at positions 368, 411, 553, 556 and 559 were associated with lower level of
resistance. Out of these variants, C316, M414T, Y448H, S556G had higher replication capacity than
other variants making them more likely to cause resistance in clinical practice [63].
Dasabuvir is administered in combination with ombitasvir-paritaprevir-ritonavir. This regimen
is referred to as 3D regimen. Ombitasvir is an NS5A inhibitor, paritaprevir is an NS3/4A inhibitor
and ritonavir is a potent inhibitor of CYP3A4 and a pharmacological booster of paritaprevir. In phase
2 and 3 clinical trials treating HCV genotype 1 infection with 3D regimen and ribavirin resulted in
95%–98% SVR [64,65]. This suggests that a multitargeted approach may maximize the response rate.
However, exposure to ombitasvir, paritaprevir, and dasabuvir can select for mutations in the NS5A,
NS3, and NS5B, respectively, thereby decreasing the activity of the specific agent in this combination.
In clinical trials, the most common mutations that emerged during treatment or on relapse among
subtype 1a infections were D168V in NS3, M28A/T/V and Q30E/K/R in NS5A, and S556G/R in
NS5B [65–68]. Mutations seen in genotype 1b relapse were Y56H and D168V in NS3, L31M and
Y93H in NS5A and S556G in NS5B at the time of relapse [65]. Consistent with the concept that
multi-targeted approaches reduce viral breakthrough, next-generation sequence analysis of patients
in the COSMOS study that included simeprevir and sofosbuvir with or without ribavirin revealed a
lack of association of treatment response to well-characterized resistance mutations [69].
4. Prevalence before and after Treatment with DAA
Under the selective pressure of DAAs, viruses with RAVs emerge that are undetectable prior
to therapy. In a landmark study, Sarrazin et al [70] found that treatment with telaprevir resulted in
the emergence of low-level resistance (V36A/M, T54A, R155K/T, A156S) and high-level resistance
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(A156V/T, 36 + 155, 33 + 156) RAVs with had frequencies inversely correlating with resistance. These
variants were detectable using subcloning up to seven months after the cessation of therapy, implying
that the minor variant may persist much longer. Similar RAVs were verified and revealed by applying
similar methods for the other first-generation protease inhibitor, boceprevir, including V55A [71].
Approximately 50% of patients that fail treatment with boceprevir have detectable RAVs [32]. Next
generation sequencing (NGS) analysis of a small number of individuals that repeatedly failed
telaprevir treatment surprisingly did not have persistent RAVs present, but apparently independently
experienced a de novo RAV generation upon treatment [72]. However the limitation of this study
was 1% frequency, and recent evidence suggests that abundancies below 0.02% may be relevant for
emergence of RAVs [73].Even in high-risk populations, treatment failure is more associated with the
emergence of a pre-existing minority variant rather than reinfection [73].
A very recent analysis attempted to refine some of the NGS data detected at least low levels of
susceptible or moderate resistance RAVs to second-generation protease inhibitor, simeprevir, in each
patient analysed [74]. The prevalence of the common NS3 Q80K RAV that affects simeprevir efficacy
is dependent on subtype and ethnic prevalence [75].
The most successful NS5B inhibitor in treatment now is sofosbuvir. Prior to full clinical
development, the S282T RAV appeared to be problematic. However, this variant appears very
rare [76,77]. Donaldson et al [74] performed an analysis on four phase III clinical trials in search
of common RAVs against sofosbuvir, discovering L159F, C316N, and V321A were associated with
virological failure [78]. Interestingly, this study also verified S282R mutation as associating with
failure. It should be noted that the majority of patients with relapse had no clear resistance variants
emerge, however there is the possibility that this is due to a lack of sensitivity in NGS technique.
NS5A RAVs can be very common, with Y93H detected in up to 15% of the population and
L31M in up to 6.3% [79]. Other RAVs tend to also be fairly common detected in approximately
0.3%–3.5% of the population. Substitutions in genotype 1a include M28T, Q30R/H, L31V, and Y93R.
Resistant variants persisted in the population beyond six months after treatment, revealing that these
variants are well tolerated [80]. This represents a major challenge as most of the next-generation
formulations include an NS5A inhibitor and there are some estimations that NS5A RAVs could persist
indefinitely [53]. Recent compelling evidence shows that daclatasvir treatment of an NS5A inhibitor
resistant variant in combination with an analogue of daclatasvir, dramatically enhances the resistance
barrier [54]. This is due to communication between NS5A molecules resulting in allosteric differences
in inhibitor binding. Table 1 summarises the data for most prevalent resistance associated variants
and drug class.
Table 1. Common RAVs; resistance and prevalence.
Drug Class Example Common RAV Resistance Prevalence
NS3/4A
inhibitor
telaprevir V36M low <1%
boceprevir T54S/A low 2%–3%
simeprevir V55A low 0.4%–3%
asunaprevir Q80K low 0.5%–75%
faldaprevir R155K high <1%
NS5A
inhibitor
daclatasvir M28 high 0.5%–4%
ombitasvir Q30 high 0.3%–1.3% (geno 1) 50%–100% (geno 3,4)
ledipasvir L31V high 0.9%–6.3% (geno 1) 74%–100%(geno 2,4)
Y93H high 1.5%–14%
NS5B NPI
sofosbuvir L159F n.d. 5.2%
V321A n.d. 2.2%
S282R low 0.4%
NS5B NNPI dasabuvir C316N low 11%–36%
Data was summarised and collated for the most prevalent RAVs [78,79,81,82]. n.d.: no data.
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5. Clinical Significance of Baseline RAVs
In sofosbuvir trials, while there were variants that emerged and were statistically significant
with resistance, the majority of subjects that experienced relapse did not carry identifiable RAVs [78].
For other drug classes, the emergence of resistant variants may be derived from a very small
proportion of the quasispecies that can only be detected with NGS, accompanied with costly
analysis. Our current understanding of the breadth and strength of resistance, in combination with
contributing host responses make response prediction based on sequence analysis untenable [83].
At this time, data need to be collected on all of these classes of drugs and the next-generation
of agents in various combinations for comprehensive understanding of how to minimize or ablate
breakthrough mutations.
6. Conclusions
HCV drug resistance is an important and upcoming clinical issue in the context of limited data
and a large number of DAA in development or approved for clinical use. Understanding the position
and mechanism of resistance may result in engineered antiviral cocktails that are highly efficacious
and minimize side-effects. The relevance of pre-existing resistance mutations for response to DAAs
needs to be better studied in order to understand their significance in selective tailoring of various
DAA for personalized care.
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